CAS 606143-52-6
:Selumetinib
Description:
Selumetinib is a small molecule inhibitor primarily known for its role as a targeted therapy in cancer treatment, particularly for tumors with mutations in the RAS signaling pathway. It specifically inhibits the activity of MEK1 and MEK2, which are key components of the mitogen-activated protein kinase (MAPK) pathway, thereby disrupting cell proliferation and survival signals in cancer cells. Selumetinib is characterized by its ability to selectively target these kinases, leading to reduced tumor growth in certain types of cancers, including non-small cell lung cancer and neurofibromatosis type 1. The compound is typically administered orally and has been studied in various clinical trials to assess its efficacy and safety profile. Its chemical structure includes a sulfonamide group, contributing to its pharmacological properties. As with many targeted therapies, selumetinib may have specific side effects, which can include gastrointestinal disturbances and skin reactions, necessitating careful monitoring during treatment. Overall, selumetinib represents a significant advancement in the field of oncology, particularly for patients with specific genetic tumor profiles.
Formula:C17H15BrClFN4O3
InChI:InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChI key:InChIKey=CYOHGALHFOKKQC-UHFFFAOYSA-N
SMILES:N(C1=C(C(NOCCO)=O)C=C2C(=C1F)N=CN2C)C3=C(Cl)C=C(Br)C=C3
Synonyms:- 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-
- 5-(4-Bromo-2-chlorophenylamino)-4-fluoro-1-methyl-1H-benzimidazole-6-carbohydroxamic acid 2-hydroxyethyl ester
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
- 6-(4-Bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
- Arry-142886
- Azd 6244
- Azd-6224
- Azd6244
- G 00039805
- Koselugo
- NSC 741O78
- Zd-6244
- Selumetinib
- selumetinib (MEK inhibitor)
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox
- AZD6244(SeluMetinib)
- SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
- AZD-6244(SeluMetinib)/AZD6244
- AZD6244, ARRY-142886, ARRY-886
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244)
- 5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
- Array142886
- 6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 12 products.
Selumetinib
CAS:SelumetinibFormula:C17H15BrClFN4O3Color and Shape:White to off white Solid-CrystalsMolecular weight:457.68145-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
CAS:Formula:C17H15BrClFN4O3Purity:95%Color and Shape:SolidMolecular weight:457.6814Selumetinib
CAS:SelumetinibFormula:C17H15BrClFN4O3Purity:≥95%Color and Shape:SolidMolecular weight:457.68Selumetinib
CAS:Selumetinib (AZD6244) is a selectivity and non-ATP-competitive MEK1/2 inhibitor. Selumetinib has antitumor activity. Cost-effective and quality-assured.Formula:C17H15BrClFN4O3Purity:98.1% - 99.90%Color and Shape:White SolidMolecular weight:457.68Selumetinib
CAS:5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamideFormula:C17H15BrClFN4O3Purity:99%Molecular weight:457.68Selumetinib
CAS:Controlled ProductApplications It is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development. It is useful as biomarker in human lung cancer cell. Potent MEK inhibitor.
References Ciardiello, F., et al.: Clin. Cancer Res., 7, 1459 (2001), Hidalgo, M., et al.: J. Clin. Oncol., 19, 3267 (2001),Formula:C17H15BrClFN4O3Color and Shape:NeatMolecular weight:457.68Selumetinib
CAS:Potent and selective MAP/ERK kinase 1/2 inhibitor. Reduces growth of tumor cells with B-Raf and Ras mutations. Tumor regression observed after chronic treatment in in vivo xenograft models. Enhances anti-tumor effect in combination with irinotecan or docetaxel.
Formula:C17H15BrClFN4O3Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:457.68 g/mol5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
CAS:Formula:C17H15BrClFN4O3Purity:95%Molecular weight:457.68
![5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxa…](https://static.cymitquimica.com/products/IN/thumb/DA0037GN.jpg)
![5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxa…](https://static.cymitquimica.com/products/10/thumb/F361876.jpg)
